deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03168464

Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

Sponsor: Bristol-Myers Squibb

Conditions Non Small Cell Lung Cancer Metastatic
Interventions Ipilimumab Nivolumab Radiation therapy
Updated 15 times since 2017 Last updated: Mar 31, 2023 Started: Oct 9, 2017 Primary completion: Mar 11, 2022 Completion: Mar 11, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual

Other terminated trials from Bristol-Myers Squibb

See all terminations from Bristol-Myers Squibb

Listed as NCT03168464, this PHASE1/PHASE2 trial focuses on Non Small Cell Lung Cancer Metastatic and remains terminated or withdrawn. Sponsored by Bristol-Myers Squibb, it has been updated 15 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jul 2017 – ~Sep 2017 · 2 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2019 · 13 months · monthly snapshot~Oct 2019 – ~Mar 2020 · 5 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Nov 2020 · 6 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jun 2022 · 9 months · monthly snapshot~Jun 2022 – ~May 2023 · 11 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. May 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Completed → Terminated

  4. Jun 2022 — May 2023 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  5. Sep 2021 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Active Not Recruiting → Recruiting

  3. May 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Oct 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2018 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Jul 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Weill Medical College of Cornell University
Data source: Weill Medical College of Cornell University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations